Ofer Rotem

1.0k citations

30 papers · 516 indexed · h-index 11

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Internal Medicine top 10%

Papers in ⓘ

Oncology 23
- Lung Cancer Research Studies 14
- Cancer Immunotherapy and Biomarkers 8
Pulmonary and Respiratory Medicine 22
- Lung Cancer Treatments and Mutations 17
- Lung Cancer Diagnosis and Treatment 6
- Brain Metastases and Treatment 4
- Advanced Breast Cancer Therapies 3

Co-authors: Alona Zer (28 shared papers)Elizabeth Dudnik (24 shared papers)Tzippy Shochat (14 shared papers)Nir Peled (16 shared papers)Aaron M. Allen (10 shared papers)Laila C. Roisman (5 shared papers)Jair Bar (9 shared papers)Damien Urban (8 shared papers)
Journals: Journal of Thoracic Oncology (7 papers)Annals of Oncology (2 papers)Lung Cancer (2 papers)Journal of Oncology (1 paper)Journal of Neuro-Oncology (1 paper)
Partner nations: Israel United States Poland

In The Last Decade

Ofer Rotem

27 papers receiving 513 citations

Peers

Countries citing papers authored by Ofer Rotem

Since Specialization

Citations

This map shows the geographic impact of Ofer Rotem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ofer Rotem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ofer Rotem more than expected).

Fields of papers citing papers by Ofer Rotem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ofer Rotem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ofer Rotem. The network helps show where Ofer Rotem may publish in the future.

Co-authors

The 25 scholars most cited alongside Ofer Rotem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ofer Rotem Line = papers co-authored together Ofer Rotem links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors Journal of Thoracic Oncology ·Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, S. Keren, Noa Popovits‐Hadari, Damien Urban, Moshe Mishaeli, Alona Zer, Aaron M. Allen, Natalie Maimon Rabinovich, Ofer Rotem, Teodor Kuznetsov, Tzippy Shochat, Laila C. Roisman, Jair Bar	2018	155
2	Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors Journal of Thrombosis and Haemostasis ·Oded Icht, Naama Darzi, Shai Shimony, Oded Jacobi, Daniel Reinhorn, Yosef Landman, Raz Mutai, Itamar Averbuch, Tzippy Shochat, Galia Spectre, Pia Raanani, Ofer Rotem, Elizabeth Dudnik, Nir Peled, Alona Zer, Avi Leader	2021	54
3	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi) Lung Cancer ·Elizabeth Dudnik, Elias Bshara, Ahuva Grubstein, Ludmila Fridel, Tzippy Shochat, Laila C. Roisman, Maya Ilouze, Anna Belilovski Rozenblum, Smadar Geva, Alona Zer, Ofer Rotem, Aaron M. Allen, Nir Peled	2018	45
4	The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer Journal of Thoracic Oncology ·Smadar Laufer‐Geva, Anna Belilovski Rozenblum, Tal Twito, R Grinberg, Addie Dvir, Lior Soussan‐Gutman, Maya Ilouze, Laila C. Roisman, Elizabeth Dudnik, Alona Zer, Ofer Rotem, Richard B. Lanman, Nir Peled	2018	40
5	Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC) Lung Cancer ·Shira Sherman, Ofer Rotem, Tzippy Shochat, Alona Zer, Assaf Moore, Elizabeth Dudnik	2020	37
6	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data OncoImmunology ·Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar, (unknown)	2021	33
7	Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung Journal for ImmunoTherapy of Cancer ·Elizabeth Dudnik, Samuel A. Kareff, Mor Moskovitz, Chul Kim, Stephen V. Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar	2021	31
8	Treatment Beyond Progression with Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Immunotherapy ·Daniel Reinhorn, Oded Jacobi, Oded Icht, Elizabeth Dudnik, Ofer Rotem, Alona Zer, Daniel A. Goldstein	2020	22
9	The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer Oncology ·Oded Jacobi, Yosef Landman, Daniel Reinhorn, Oded Icht, Michal Sternschuss, Ofer Rotem, Inbar Finkel, Aaron M. Allen, Elizabeth Dudnik, Daniel A. Goldstein, Alona Zer	2021	20
10	Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study Neuro-Oncology Advances ·Nir Peled, Waleed Kian, Edna Inbar, Iris M. Goldstein, Melanie Zemel, Ofer Rotem, Anna Belilovski Rozenblum, Hovav Nechushtan, Elizabeth Dudnik, Daniel Levin, Alona Zer, Shoshana Keren-Rosenberg, Shlomit Yust‐Katz, Vered Fuchs, Areen Abu Remilah, Ilan Shelef, Laila C. Roisman	2021	18
11	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors Frontiers in Oncology ·Elizabeth Dudnik, Jair Bar, Assaf Moore, Teodor Gottfried, Mor Moskovitz, Julia Dudnik, Tzippy Shochat, Aaron M. Allen, Alona Zer, Ofer Rotem, Nir Peled, Damien Urban	2021	14
12	Efficacy and Safety of <b><i>ALK</i></b> Tyrosine Kinase Inhibitors in Elderly Patients with Advanced <b><i>ALK</i></b>-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort Oncology Research and Treatment ·Aseel Bedas, Nir Peled, Natalie Maimon Rabinovich, Moshe Mishaeli, Tzippy Shochat, Alona Zer, Ofer Rotem, Aaron M. Allen, Jair Bar, Elizabeth Dudnik, (unknown)	2019	8
13	OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data Journal of Thoracic Oncology ·Elizabeth Dudnik, Mor Moskovitz, Abed Agbarya, Teodor Kuznetsov, Tzippy Shochat, Damien Urban, M. Wollner, Alona Zer, Ofer Rotem, Nir Peled, Jair Bar	2019	6
14	Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents? Thoracic Cancer ·Michal Sternschuss, Nir Peled, Aaron M. Allen, Elizabeth Dudnik, Ofer Rotem, Noga Kurman, Omer Gal, Hiba Reches, Alona Zer	2020	6
15	Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer Asia-Pacific Journal of Clinical Oncology ·Oded Icht, Liran Domachevsky, David Groshar, Elizabeth Dudnik, Ofer Rotem, Aaron M. Allen, Nir Peled, Daniel Reinhorn, Oded Jacobi, Tzippy Shochat, Hanna Bernstine, Alona Zer	2020	4
16	Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer: The Davidoff Cancer Center Experience. PubMed ·Elizabeth Dudnik, Aaron M. Allen, Natalia Michaeli, Aleksandra Benouaich-Amiel, Tzippy Shochat, Nir Peled, Inbar Finkel, Alona Zer, Ofer Rotem, Shlomit Yust‐Katz	2020	4
17	Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature Thoracic Cancer ·Itamar Averbuch, Roi Tschernichovsky, Oded Icht, Daniel A. Goldstein, Raz Mutai, Elizabeth Dudnik, Ofer Rotem, Nir Peled, Aaron M. Allen, Smadar Laufer‐Geva, Yael Goldberg, Alona Zer	2023	3
18	Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy Biomedicines ·Ofer Rotem, Alona Zer, Lilach Yosef, Einat Beery, Hadar Goldvaser, Anna Gutkin, Ron Levin, Elizabeth Dudnik, Tamar Berger, Meora Feinmesser, Adva Levy‐Barda, Meir Lahav, Pia Raanani, Orit Uziel	2023	3
19	Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC Journal of Oncology ·Omer Gal, Elizabeth Dudnik, Ofer Rotem, Inbar Finkel, Idit Peretz, Alona Zer, Jacob Mandel, Alexandra Amiel, Tali Siegal, Jair Bar, Anastasiya Lobachov, Shlomit Yust	2020	3
20	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study Breast Cancer Research and Treatment ·Daniel Reinhorn, Iryna Kuchuk, Tzippy Shochat, Bella Nisenbaum, Aarón Sulkes, Daniel Hendler, Ofer Rotem, Daliah Tsoref, Olga Olitzky, Hadar Goldvaser, Michal Sarfaty, Victoria Neiman, Judit Prus, Maya Gottfried, Shlomit Yust‐Katz, Rinat Yerushalmi	2021	2

About Ofer Rotem

Ofer Rotem is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Epidemiology, having authored 30 papers that have together received 516 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (14 papers), Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Diagnosis and Treatment (6 papers), Brain Metastases and Treatment (4 papers), Cancer Genomics and Diagnostics (4 papers), Advanced Breast Cancer Therapies (3 papers) and Neuroendocrine Tumor Research Advances (3 papers). The work is most often cited by research in Oncology (379 citations), Internal Medicine (38 citations), Pulmonary and Respiratory Medicine (312 citations), Cancer Research (99 citations) and Pathology and Forensic Medicine (84 citations). Ofer Rotem has collaborated with scholars based in Israel, United States and Poland. Frequent co-authors include Alona Zer, Elizabeth Dudnik, Tzippy Shochat, Nir Peled, Aaron M. Allen, Laila C. Roisman, Jair Bar, Damien Urban, Mor Moskovitz and Mira Wollner. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer, Journal of Oncology and Journal of Neuro-Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact